The role of transcription factor proteins in mutagenesis at regulatory sites

NIH RePORTER · NIH · R01 · $336,835 · view on reporter.nih.gov ↗

Abstract

ABSTRACT More than 90% of cancer somatic mutations fall in non-coding regions of the genome. While the vast majority of these mutations are expected to be passengers, a small fraction could act as drivers by disrupting regulatory interactions between transcription factors (TFs) and DNA, leading to dysregulation of gene expression. Despite the increased availability of whole-genome cancer somatic mutation data, identifying non-coding driver mutations in TF binding sites remains a challenge, likely because of gaps in our understanding of the mutagenic processes acting on regulatory DNA. There is increasing evidence that TFs bound to the genome can interfere with normal DNA replication and repair, which could lead to increased mutation rates. However, the precise molecular mechanisms of these interactions are poorly understood. The current project will address this gap in our understanding of mutagenesis in TF binding sites by using new experimental techniques and computational models to directly investigate the molecular mechanisms by which TF binding can lead to genetic mutations. Our overarching hypothesis is that TFs bound to genomic sites containing DNA lesions can lead to inefficient repair/correction of the lesions, and consequently to increased mutation rates. Among DNA lesions we will focus on base mismatches, which are important precursors for a majority of cancer mutations, and are frequently generated in the genome during DNA replication, recombination, and even repair of other lesions. Thus, mismatches retained in cancer genomes due to being bound by TF proteins are expected to have a large contribution to the hyper-mutation signal observed at TF binding sites. It is therefore critical to characterize the TF-DNA binding landscape in the presence of DNA mismatches (Aim 1), and to thoroughly investigate the mechanisms by which TF binding to mismatches can lead to genetic mutations (Aim 2). Overall, our proposed work represents a first step toward determining whether the enrichment of cancer mutations in TF binding sites is due, at least in part, to DNA-bound TFs that act as roadblocks for DNA mismatch correction and repair. Longer term, a thorough understanding of the role of TFs in mutagenesis at regulatory DNA will be instrumental for developing accurate methods to identify regulatory driver mutations in cancer.

Key facts

NIH application ID
10092203
Project number
5R01GM135658-02
Recipient
DUKE UNIVERSITY
Principal Investigator
Raluca Gordan
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$336,835
Award type
5
Project period
2020-02-01 → 2024-01-31